| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2018-04-10 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics plc | 5,140,289 | 14.0% | EDGAR |
| SC 13G/A | 2018-02-12 | Vivo Capital VIII, LLC | Nabriva Therapeutics plc | 4,074,190 | 11.1% | EDGAR |
| SC 13G/A | 2018-02-09 | venBio Global Strategic Fund II L.P. | Nabriva Therapeutics plc | 2,122,962 | 5.8% | EDGAR |
| SC 13G/A | 2018-02-05 | Global Life Bioventure IV S.a.r.l. | Nabriva Therapeutics plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-02 | Novo Holdings A/S | Nabriva Therapeutics plc | 2,924,822 | 8.0% | EDGAR |
| SC 13D/A | 2018-01-26 | ORBIMED ADVISORS LLC | Nabriva Therapeutics plc | 3,919,600 | 14.6% | EDGAR |
| SC 13D/A | 2018-01-26 | ORBIMED ADVISORS LLC | Nabriva Therapeutics plc | 3,919,600 | 14.6% | EDGAR |
| SC 13G/A | 2017-10-10 | HBM Healthcare Investments (Cayman) Ltd. | Nabriva Therapeutics plc | 2,334,008 | 6.4% | EDGAR |
| SC 13G/A | 2017-07-10 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics AG | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-02-13 | venBio Global Strategic Fund II L.P. | Nabriva Therapeutics AG | 222,296 | 8.2% | EDGAR |
| SC 13G/A | 2017-02-13 | Vivo Capital VIII, LLC | Nabriva Therapeutics AG | 4,021,559 | 14.8% | EDGAR |
| SC 13G/A | 2017-02-10 | Phase4 Partners Ltd | Nabriva Therapeutics AG | 159,882 | 5.9% | EDGAR |
| SC 13G | 2017-02-09 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics AG | 1,960,310 | 7.2% | EDGAR |
| SC 13G/A | 2017-02-08 | Novo A/S | Nabriva Therapeutics AG | 232,655 | 8.6% | EDGAR |
| SC 13G | 2016-07-29 | Novo A/S | Nabriva Therapeutics AG | 106,511 | 5.0% | EDGAR |
| SC 13G/A | 2016-05-10 | WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | Nabriva Therapeutics AG | 1,354 | 0.1% | EDGAR |
| SC 13G | 2016-04-29 | venBio Global Strategic Fund II L.P. | Nabriva Therapeutics AG | 117,787 | 5.6% | EDGAR |
| SC 13G | 2016-03-23 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics AG | 237,888 | 11.2% | EDGAR |
| SC 13G | 2016-02-12 | Phase4 Partners Ltd | Nabriva Therapeutics AG | 159,882 | 7.6% | EDGAR |
| SC 13G | 2016-02-12 | WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | Nabriva Therapeutics AG | 1,196,955 | 5.7% | EDGAR |